Search Results
Your search for ,maY matches 17186 pages
Showing 151 - 200Is Long-Term PPI Use Associated With Increased Gastric Cancer Risk?
Long-term proton pump inhibitor (PPI) use may not be associated with an increased risk of gastric adenocarcinoma, according to findings from a Nordic health study published by Duru et al The BMJ. According to the report's authors, “This finding should offer relief for patients needing long-term...
Outcomes With Colorectal Cancer Screening Among Childhood Cancer Survivors Who Received Abdominopelvic Radiation
In a study reported in the Journal of Clinical Oncology, Yeh et al found that childhood cancer survivors who received abdominopelvic radiation, who are at increased risk of developing colorectal cancer, can benefit from early screening to reduce the risk of colorectal cancer and associated...
Cancer Workforce Challenges Undermine Patient Care and Jeopardize Momentum in Research, Report Finds
The U.S. cancer workforce faces critical challenges that may affect Americans' access to lifesaving cancer care and delay progress in cancer research. A new report from the President's Cancer Panel, Ensuring a Strong Future for America's Cancer Workforce, underscores these key issues—including...
Colorectal Cancer: How Does Lifetime Alcohol Consumption Affect Risk?
Studies have demonstrated a link between alcohol consumption and an elevated risk of colorectal cancer. New research now reveals that higher lifetime alcohol consumption is also associated with a higher risk, especially for rectal cancer, and that quitting drinking can lower a person’s risk. The...
A Battle With My Blood
Editor’s note: On November 22, 2025—the 62nd anniversary of her grandfather President John F. Kennedy’s assassination—Tatiana Celia Kennedy Schlossberg published an essay in The New Yorker detailing her diagnosis of acute myeloid leukemia with chromosome 3 inversion, a rare and aggressive subtype...
Medical Societies Caution Misinformation May Drive Underuse of Lung Cancer Screening
Repeated methodological flaws in published research result in misinformation that may cause eligible patients to forgo or not be offered lung cancer screening, according to a joint publication from the Society of Thoracic Surgeons (STS), American Society for Radiation Oncology (ASTRO), and American ...
Phased Variant ctDNA as Biomarker After First-Line Treatment in LBCL
In a study (DIRECT) reported in the Journal of Clinical Oncology, Krupka et al found that phased variant (PV) ctDNA provided “sensitive and clinically meaningful response assessment” after first-line treatment of large B-cell lymphoma (LBCL). As stated by the investigators, “Tracking tumor-specific ...
Limited or No State Regulation of STLD Health Plans Linked to Decreases in Timely Cancer Treatment Initiation
In 2018, the federal government expanded the coverage duration of short-term limited-duration (STLD) health plans from 3 months to less than 12 months, with the option to renew for a total duration of up to 36 months. Some states imposed more stringent regulations than those federally imposed or...
Meningiomas: Phase II Trial Shows Activity of Targeted Therapy
A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that the CDK 4/6 inhibitor abemaciclib may slow tumor growth in patients with aggressive meningiomas that have specific genetic mutations. The primary analysis of Alliance A071401 was published by Priscilla...
Popular Supplement May Interfere With Cancer Treatment
For many patients with cancer, hair loss can be one of the most distressing side effects of their therapy. Increasingly, patients have been taking oral supplements of biotin, which are marketed to consumers for their potential to improve hair regrowth and brittle nails. However, there is little...
Intensity-Modulated Proton vs Photon Radiotherapy in Oropharyngeal Cancer
In a prespecified interim analysis of a phase III trial (University of Texas MD Anderson Cancer Center Clinical Trial Consortium trial) reported in The Lancet, Frank et al found that intensity-modulated proton therapy (IMPT) was noninferior to standard intensity-modulated photon radiation therapy...
Axillary Recurrence With or Without ALND in Patients With Residual Micrometastases After Neoadjuvant Chemotherapy for Breast Cancer
In an initial analysis of a retrospective cohort study (OPBC-07/microNAC) reported in The Lancet Oncology, Montagna et al found that available evidence did not provide support for axillary lymph node dissection (ALND) in all patients with ypN1mi disease in sentinel lymph nodes after neoadjuvant...
HCC: LLM Advice and Treatment Concordance
Commonly used large language models (LLMs) were able to provide appropriate, guideline-aligned treatment recommendations for patients with straightforward cases of early-stage hepatocellular carcinoma; however, greater disagreement with physician recommendations was seen in cases of late-stage...
What Is Causing a Rise in Early-Onset Gastrointestinal Cancers, Including Pancreatic Cancer?
Although it’s been widely reported for years that colorectal cancer incidence has been increasing among younger adults under age 50 by between 1% and 2% annually since the mid-1990s,1 two new studies by Kimmie Ng, MD, MPH, Associate Chief of the Division of Gastrointestinal Oncology and Founding...
Breast Cancer Risk May Be Linked to Physical Activity Levels in Adolescence
Recreational physical activity may be associated with breast tissue composition and oxidative stress levels in adolescent girls, independent of body fat percentages, according to research findings published in Breast Cancer Research. “The importance and urgency of this research are underscored by...
ctDNA Positivity After Neoadjuvant T-DM1 May Predict HER2-Positive Breast Cancer Recurrence
Excluding skin cancers, breast cancer is the most commonly diagnosed cancer among women in the United States, accounting for about 30% of all new female cancers each year. In 2026, the American Cancer Society estimates that 322,000 new cases of invasive breast cancer and about 61,000 new cases of...
Global Cancer Survival Gaps Assessed Using a Country-Level Machine-Learning Framework
A machine-learning model has calculated country-specific cancer mortality-to-incidence ratios and evaluated the factors that contribute the most to each country's survival gaps. Additionally, the artificial intelligence (AI) tool mapped out actions each country could take to improve cancer...
Can a Genetic Variant Affect the Efficacy of Abiraterone?
Data from a major clinical trial from the Alliance for Clinical Trials in Oncology have uncovered a genetic factor that may inform how to optimize the dosing of abiraterone, a widely used hormonal treatment for advanced prostate cancer. Published by Norton et al in Clinical and Translational...
Dina Ioffe, MD, on Disparities in HCC: Do They Affect Systemic Care?
Dina Ioffe, MD, of Fox Chase Cancer Center, describes the results of an analysis that sought to determine how race/ethnicity, insurance status, and socioeconomic status may affect patterns of systemic treatment for metastatic hepatocellular carcinoma (HCC) (Abstract 489).
SCLC: Small Study Tests Efficacy of CTCs in Predicting Response to Tarlatamab
A research team has discovered that a particular marker on circulating tumor cells (CTCs) may indicate whether a patient with small cell lung cancer (SCLC) will experience a lasting response to tarlatamab-dlle, a newly approved immunotherapy. The findings, which were published by Mishra in Cancer...
Improved Contralateral Breast Cancer Risk Knowledge With Personalized Counseling Tool
Patients with unilateral breast cancer who underwent quantitative counseling with a personalized tool incorporating genetic testing results were better informed of their contralateral breast cancer risk compared with those who received standard counseling, according to results from the GET FACTS...
Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides
A deep learning model demonstrated the ability to predict breast cancer recurrence risk and possible benefit from the addition of chemotherapy based on histopathologic images rather than genomic testing in patients with hormone receptor–positive, HER2-negative breast cancer, according to findings...
Novel Endocrine Therapy, Giredestrant, Improves Invasive Disease–Free Survival in Estrogen Receptor–Positive, HER2-Negative Early Breast Cancer
Giredestrant, a next-generation oral selective estrogen receptor degrader (SERD) and full antagonist, significantly improved invasive disease–free survival as adjuvant treatment for patients with estrogen receptor–positive, HER2-negative early breast cancer compared with standard-of-care endocrine...
Can DNA Testing of Colorectal Polyps Improve Insight Into Genetic Risks?
It is estimated that hereditary factors play a role in about 5% to 10% of colorectal cancer cases, with a higher prevalence of hereditary factors seen in younger patients. Many colorectal polyps are considered potential precursors to cancer: at least 10 polyps in individuals younger than 60 years...
Multiple Myeloma: Sex Differences in Etiology and Clinical Presentation
Rates of multiple myeloma, the second most common blood cancer in the United States, are increasing and are twice as high in men than in women. A new study published by Ong et al in the journal Cancer provides insights that may help to explain this disparity. To investigate the sex difference in...
FDA Increases Flexibility on Requirements for Cell and Gene Therapies
The U.S. Food and Drug Administration (FDA) has announced it is sharing information about the agency’s flexible approach to overseeing chemistry, manufacturing, and control (CMC) requirements for cell and gene therapies (CGTs). The agency’s more flexible approach has been, and is expected to...
MajesTEC-3: ‘Unprecedented’ Benefit in Previously Treated Multiple Myeloma
For patients with previously treated multiple myeloma, the greatest risk reduction yet achieved in a phase III clinical trial was reported with the BCMA-directed CD3 T-cell engager teclistamab-cqyv plus daratumumab and hyaluronidase-fihj. Treatment with this combination resulted in an 83% reduction ...
Can KDM6A Mutations Help Guide Treatment Selection in Bladder Cancer?
Mutations in KDM6A have been identified as a regulator of therapeutic responses in advanced bladder cancer, sensitizing tumors to anti–PD-1 immune checkpoint inhibition but resisting cisplatin chemotherapy, according to early research published in Nature Communications. Based on this and further...
In Head-to-Head Comparison, Fixed-Duration Treatment Noninferior to Continuous for Previously Untreated CLL
Based on the phase III CLL17 trial, a fixed duration of targeted treatment demonstrated noninferiority to continuous treatment with respect to progression-free survival in previously untreated patients with chronic lymphocytic leukemia (CLL). The findings were presented at the Plenary Session of...
Researchers Create Immune Cell Atlas of Bone Marrow in Patients With Multiple Myeloma
Scientists at several institutions across the country, in partnership with the Multiple Myeloma Research Foundation (MMRF), have helped generate the largest single-cell immune cell atlas of the bone marrow in patients with multiple myeloma. The findings, published by Pilcher et al in Nature Cancer, ...
Small Study Examines Potential of Artificial Saliva in Patients With Head and Neck Cancer
An artificial saliva in the form of a mouthwash, produced with a protein extracted from sugarcane and modified in a laboratory, may aid in treating hyposalivation among patients with head and neck cancer, a new study has found. Radiotherapy delivered very close to the mouth can destroy salivary...
Are Food Preservatives Linked to Increased Cancer Risk?
Higher intake of food preservatives, widely used in industrially processed foods and beverages to extend shelf life, is associated with a modestly increased risk of cancer, according to the results of a French study published by Hasenböhler et al in The BMJ. While further research is needed to...
Early Results Show Pirtobrutinib Matches Ibrutinib in BTK Inhibitor-Naive CLL
In the phase III BRUIN CLL-314 trial, response rates were found to be as good with the noncovalent Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib as with ibrutinib in both patients with treatment-naive and relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic...
Benefit of Azacitidine Plus Venetoclax Confirmed in AML
The combination of the hypomethylating agent azacitidine and the BCL2 inhibitor venetoclax is an established regimen in older, unfit patients with acute myeloid leukemia (AML). Now, a phase II randomized trial indicates potential for less intensive therapy in the newly diagnosed fit population. In...
Using AI to Ensure That All Patients With Cancer Have Access to Precision Oncology Care
Steve Brown, Founder and Chief Executive Officer of CureWise (curewise.com), an artificial intelligence (AI)-driven patient advocacy app, describes his year-long quest to understand a series of symptoms that ultimately led to a diagnosis of light chain (AL) amyloidosis—a disease closely related to ...
Study Finds GLP-1 RAs May Influence Colorectal Cancer Mortality
Colon cancer is among the leading causes of cancer-related morbidity and mortality both in the United States and globally. Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may influence cancer mortality, and the results from a new study may add to that mounting ...
Do GLP-1 RAs Reduce the Risk of Developing Colorectal Cancer More Than Aspirin?
Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. According to the American Cancer Society, in 2025, about 154,270 individuals were diagnosed with colorectal cancer, and approximately 53,000 individuals died from the...
BRAF V600E–Mutant Colorectal Cancer: First-Line Encorafenib, Cetuximab, and FOLFIRI
New results from the BREAKWATER trial show that the targeted therapy combination of encorafenib and cetuximab with the chemotherapy fluorouracil, folinic acid, and irinotecan (FOLFIRI) can reduce the size or number of tumors in patients with BRAF V600E–mutant metastatic colorectal cancer. Adding...
AI-Based Imaging Model Predicts Extranodal Extension Burden and Improves Risk Stratification in Oropharyngeal Cancer
Prediction of the number of lymph nodes with extranodal extension in patients with oropharyngeal carcinoma through a deep learning imaging platform for autosegmentation may help to guide pretreatment patient risk stratification and treatment decision-making, according to the results of a multisite, ...
High Neighborhood Fast Food Expenditure and Early-Onset Colorectal Cancer
Studies show that while the overall rates of colorectal cancer are decreasing, for individuals younger than age 50, the incidence has risen by an alarming 50% since the mid-1990s. While the exact causes are unknown, poor diet and alcohol consumption are believed to be contributing factors. A study...
Most People Trust AI Less Than Physicians, Survey Finds
Two national surveys examining trust and acceptance of medical artificial intelligence (AI) have found that while most people are reluctant to use AI tools to diagnose their health condition, they see potential in the technology’s ability to help diagnose cancer. The findings, published by Sobolev...
HCC: Real-World Patterns of Systemic Therapy, Sequencing, and Survival
A recent retrospective cohort study has described the current treatment patterns, sequencing, and survival outcomes among patients receiving systemic therapy for hepatocellular carcinoma (HCC). The findings, which were published by Lau-Min et al in JAMA Network Open, showed that...
County-Level Obesity Prevalence May Predict Obesity-Related Cancer Rates in Young Adults
The International Agency for Research on Cancer has linked obesity to increases in the development of 13 cancers, including breast, colorectal, kidney, endometrial, thyroid, pancreatic, liver, multiple myeloma, gastric cardia, meningioma, ovarian, esophageal, and gallbladder cancers. Now, a new...
A Novel Paradigm in Acute Kidney Injury: Congestive Nephropathy in RCC With IVC Thrombus
Researchers have proposed a new mechanism of acute kidney injury to account for patients with renal cell carcinoma (RCC) who have an inferior vena cava (IVC) tumor thrombus, according to findings presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO).1 By analyzing...
Study Explores Association of GLP-1 RAs With Risk of Obesity-Related Cancers
The development of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has revolutionized the management of obesity and type 2 diabetes. The agents offer therapeutic potential in a host of other conditions, including cardiovascular, liver, and neurodegenerative diseases, as well as the...
Molecular Analysis Reveals Underlying Sex-Linked Multiple Myeloma Progression Patterns
Researchers have uncovered that sex-specific dysregulation of exosomal non-coding RNAs may drive different patterns of disease progression of multiple myeloma in male and female individuals, according to findings published in Blood Cancer Journal. “The same therapies are provided for men and women ...
NSAIDs May Improve Survival in Postoperative ctDNA-Positive Patients With Colon Cancer
Circulating tumor DNA (ctDNA) levels may help to determine which patients with colon cancer could benefit from the addition of nonsteroidal anti-inflammatory drugs (NSAIDs), such as celecoxib, to chemotherapy following surgery, according to findings from a post hoc analysis of the CALGB/SWOG 80702...
Lymphocyte Kinetics After CAR T-Cell Infusion May Predict Survival Outcomes in Non-Hodgkin Lymphoma
A higher absolute lymphocyte count (ALC) after receipt of chimeric antigen receptor (CAR) T-cell therapy may be associated with improved progression-free and/or overall survival in patients with non-Hodgkin lymphoma, according to findings from the 2025 American Society of Hematology (ASH) Annual...
FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection
On December 17, the U.S. Food and Drug Administration (FDA) approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for subcutaneous injection for adult patients across all indications approved for the intravenous formulation of amivantamab (Rybrevant). PALOMA-3 The subcutaneous injection of ...
CD123-Targeting ADC Shows Activity in AML and BPDCN
Researchers presented new data from two ongoing studies of pivekimab sunirine, an antibody-drug conjugate targeting CD123, in treating two aggressive blood cancers at the 2025 American Society of Hematology (ASH) Annual Meeting & Exposition. In a phase Ib/II trial led by Naval Daver, MD,...
